Literature DB >> 18811602

Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication.

R M Rabello-Fonseca1, D R Azulay, R R Luiz, C A Mandarim-de-Lacerda, T Cuzzi, M Manela-Azulay.   

Abstract

BACKGROUND: Despite evidences of the beneficial clinical effects of oral isotretinoin in the treatment of cutaneous photoaging, scientific evidences are still scarce, mainly supported by histopathological and morphometric studies.
OBJECTIVES: To analyse possible clinical and morphological changes resulting from the treatment of photoaging with oral isotretinoin.
METHODS: Thirty female patients, aged 40 to 55 years, phototypes II to IV, with moderate to severe photoaging were randomly assigned to two groups of 15 each. Group I (G I) patients were treated with 10 mg of isotretinoin and group II (G II) with 20 mg of oral isotretinoin thrice a week for 3 months. Skin biopsies were performed before and after the end of therapy, and the various sections were submitted to specific staining for collagen and elastic fibres. To analyse the changes, morphometric studies were performed, and the results obtained were analysed by Student's t-test (paired and non-paired). Clinical results of therapy regarding texture, colouring and aspect of the wrinkles were assessed by both physician and patient.
RESULTS: The increase in the amount of collagen fibres was statistically significant with both dosage regimens (mean, 37.8%, increasing to 44.4%; P = 0.029 with the 10-mg dosage; and mean, 36.6%, increasing to 41.9%; P = 0.01 with the 20-mg dosage). A pattern pointing toward a decrease in the number of elastic fibres was found (mean, 15.3-12%; P = 0.014 with the 10-mg dosage; mean, 15.5-14%; P = 0.125 with the 20-mg dosage). Additionally, there was improvement in the general aspect of the skin, regarding texture, wrinkles depth and skin coloration. LIMITATIONS: Despite ethical considerations, a lack of a control group using placebo may render the results less accurate.
CONCLUSION: Low dosages of oral isotretinoin seem to be an effective therapeutic option for cutaneous photoaging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18811602     DOI: 10.1111/j.1468-3083.2008.02947.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

Review 1.  Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.

Authors:  Steven Brandon Nickle; Nathan Peterson; Michael Peterson
Journal:  J Clin Aesthet Dermatol       Date:  2014-04

2.  Oral isotretinoin in photoaging: objective histological evidence of efficacy and durability.

Authors:  Bruna Souza Felix Bravo; David Rubem Azulay; Ronir Raggio Luiz; Carlos Alberto Mandarim-De-Lacerda; Tullia Cuzzi; Mônica Manela Azulay
Journal:  An Bras Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.896

3.  Safety of Performing Superficial Chemical Peels in Patients on Oral Isotretinoin for Acne and Acne-Induced Pigmentation.

Authors:  Chandrashekar Bs; Sree Lalitha Vadlamudi; Chaithra Shenoy
Journal:  J Clin Aesthet Dermatol       Date:  2021-11

4.  Severe hyperpigmentation and scarring following glycolic acid peel treatment in combination with low-dose isotretinoin.

Authors:  Peter Arne Gerber; Gabriela Kukova; Edwin Bölke; Bernhard Homey; Evelyn Diedrichson
Journal:  Eur J Med Res       Date:  2014-11-07       Impact factor: 2.175

5.  Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology.

Authors:  Ediléia Bagatin; Caroline Sousa Costa; Marco Alexandre Dias da Rocha; Fabíola Rosa Picosse; Cristhine Souza Leão Kamamoto; Rodrigo Pirmez; Mayra Ianhez; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2020-10-03       Impact factor: 1.896

6.  Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions.

Authors:  Sherman Chu; Lauren Michelle; Chloe Ekelem; Calvin T Sung; Nathan Rojek; Natasha A Mesinkovska
Journal:  Arch Dermatol Res       Date:  2020-11-05       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.